Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STXS 
Stereotaxis Inc (STXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: STXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.33
1 Year Target Price $4.33
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.18% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 275.93M USD | Price to earnings Ratio - | 1Y Target Price 4.33 |
Price to earnings Ratio - | 1Y Target Price 4.33 | ||
Volume (30-day avg) 4 | Beta 1.65 | 52 Weeks Range 1.54 - 3.59 | Updated Date 10/18/2025 |
52 Weeks Range 1.54 - 3.59 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.43% | Operating Margin (TTM) -45.2% |
Management Effectiveness
Return on Assets (TTM) -35.03% | Return on Equity (TTM) -198.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 280901090 | Price to Sales(TTM) 8.68 |
Enterprise Value 280901090 | Price to Sales(TTM) 8.68 | ||
Enterprise Value to Revenue 8.83 | Enterprise Value to EBITDA -10.06 | Shares Outstanding 91067464 | Shares Floating 63519283 |
Shares Outstanding 91067464 | Shares Floating 63519283 | ||
Percent Insiders 30 | Percent Institutions 46.26 |
Upturn AI SWOT
Stereotaxis Inc
Company Overview
History and Background
Stereotaxis Inc. was founded in 2001. It develops robotic magnetic navigation technology for use in interventional cardiology and electrophysiology procedures. The company's technology aims to improve the precision and safety of catheter-based procedures.
Core Business Areas
- Robotic Navigation Systems: Develops and markets robotic magnetic navigation systems, including the Genesis RMN system, used for remote-controlled navigation of cardiac catheters.
- Consumables: Sells disposable devices and accessories used with its robotic navigation systems, such as magnetic ablation catheters and guidewires.
- Service and Support: Provides installation, training, and ongoing service and support for its installed base of robotic navigation systems.
Leadership and Structure
David Fischel is the Chairman and CEO. The company has a board of directors and a management team overseeing various departments including R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Genesis RMN System: A robotic magnetic navigation system used for cardiac ablation procedures. It offers precise catheter control and navigation. Limited specific market share data is available. Competitors include Biosense Webster (JNJ), Abbott (ABT), and Boston Scientific (BSX) who offer electrophysiology solutions.
- Magnetic Ablation Catheters: Disposable catheters designed for use with the Genesis RMN system. These catheters enable precise lesion creation during ablation procedures. Market share for specific catheter types is difficult to ascertain. Competitors include Biosense Webster (JNJ), Abbott (ABT), and Boston Scientific (BSX).
Market Dynamics
Industry Overview
The electrophysiology market is growing due to the increasing prevalence of cardiac arrhythmias and advancements in ablation technology. The market is competitive, with several large medical device companies offering various solutions.
Positioning
Stereotaxis Inc. is positioned as a provider of robotic navigation technology for electrophysiology procedures, offering precision and control compared to manual catheter navigation. However, it competes with established players with broader product portfolios.
Total Addressable Market (TAM)
The total addressable market for electrophysiology devices, including ablation catheters and navigation systems, is estimated to be in the billions of dollars annually. Stereotaxis is positioned to capture a portion of this market with its robotic technology but faces challenges in adoption and competition.
Upturn SWOT Analysis
Strengths
- Robotic Navigation Technology
- Increased Precision and Safety
- Potential for Reduced Procedure Times
- Differentiated product offering
Weaknesses
- Limited Market Share
- High System Cost
- Dependence on Robotic Technology Adoption
- Profitability
Opportunities
- Expanding Electrophysiology Market
- Increasing Prevalence of Cardiac Arrhythmias
- Growing Demand for Minimally Invasive Procedures
- Partnerships with hospitals
Threats
- Competition from Established Medical Device Companies
- Technological Advancements by Competitors
- Reimbursement Pressures
- Regulatory changes
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- BSX
Competitive Landscape
Stereotaxis has a technologically advanced solution for electrophysiology. However, JNJ, ABT and BSX have scale advantages.
Growth Trajectory and Initiatives
Historical Growth: Historical revenue and sales figures are needed to determine past growth.
Future Projections: Analyst estimates are required to forecast future revenue and earnings growth.
Recent Initiatives: Requires access to company announcements and reports on any new product launches, partnerships, or strategic initiatives.
Summary
Stereotaxis has a unique robotic technology, but faces challenges with profitability and market share against larger competitors. The company needs to effectively promote the benefits of its robotic system to gain wider adoption. Reimbursement and technological advancements by competitors need to be closely monitored. Strategic partnerships and new applications could drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (Estimates)
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stereotaxis Inc
Exchange NYSE MKT | Headquaters Saint Louis, MO, United States | ||
IPO Launch date 2004-08-12 | CEO & Chairman Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 139 | Website https://www.stereotaxis.com |
Full time employees 139 | Website https://www.stereotaxis.com | ||
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminating the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; V-CAS; and MAGiC catheter for cardiac ablation procedures. Further, it provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.